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ABSTRACT 
    Breast cancer has a high prevalence among women and most patients suffer 
from metastasis to bone. The mechanisms involved in breast cancer bone metastasis 
are poorly understood. Three-dimensional (3D) tissue culture systems are becoming 
a focus of biomedical engineering. The 3D cultures can mimic the in vivo 
microenvironment and have much greater biological relevance than the traditional 
two-dimensional (2D) monolayer cell culture systems. There is a need for developing 
reliable in vitro models to study the mechanism of bone metastasis in breast cancer. 
We established a 3-dimensional (3D) collagen matrix tissue culture model to study 
metastatic breast cancer. Calcitriol or 1, 25 dihydroxyvitamin D3 has anti-tumor 
effects by inhibiting cancer cell proliferation and inducing differentiation. There are 
few research studies investigating its role in metastasis. None of the research studies 
were based on bio-mimetic 3D models. We used this novel 3D tissue culture system 
to test 1, 25 dihydroxyvitamin D3’s role in breast cancer bone metastasis. Our results 
demonstrate vitamin D pretreated breast cancer cells had significantly decreased (p 
≤ 0.0001) migration rate, in association with significantly decreased (p ≤ 0.05) cell 
surface expression of CXCR4. This result proved the hypothesis vitamin D inhibits 
breast cancer bone metastasis by down regulating CXCR4 expression. Our data 
showed in the 3D system, breast cancer migration rate increased significantly 
compared with those in 2D system. In our pilot study, CXC12 expression data 
suggest that the decrease in migration was not due to the CXCR4-CXCL12 axis 
because there was no significant difference (p ≥ 0.05) of CXCL12 expression 
between 3D and 2D osteoblast cells. The CXC12 studies needs to be validated with a 
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larger sample size. Alternatively, this observation suggests that there are other 
signaling pathways which influence the migration of breast cancer cells towards 
osteoblast cells and bone matrix. 
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CHAPTER 1 
INTRODUCTION 
Background 
Bone is one of the most preferential metastatic target sites for cancers 
including breast cancer. Most breast cancer patients will develop bone metastasis. 
It can cause severe pain, pathologic fractures, life threatening hypercalcemia, 
spinal cord compression, and other nerve compression syndromes [1]. Although 
the cancer incidence and mortality remain severe, the mechanisms of breast 
cancer bone metastasis are poorly understood. This makes it difficult to find 
effective chemotherapeutic agents. Based on some existing research studies, 
vitamin D could decrease the migration of breast cancer cells in two-dimensional 
(2D) models. To our best knowledge, no studies have used a three-dimensional 
(3D) model containing collagen matrix, which is an important component of bone, 
to study the inhibiting effect. To study the modulating effect of 1, 25 
dihydroxyvitamin D3, we compared the efficiency of the inhibiting effect of vitamin 
D between 2D and 3D models in this study.  
    Chemokines are believed to be associated with the metastasis of various 
types of cancers. The CXCL12/CXCR4 signaling axis is one of the well-known 
mediators of breast cancer metastasis. The CXCR4 expressing human breast 
cancer cells can easily home to the organs which has high expression of its ligand, 
CXCL12. The expression of CXCR4 in human specimens is also a marker for 
prognosis. In this study, we looked for the differences in the expression of CXCR4 
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between 1, 25 dihydroxyvitamin D3 treated and untreated breast cancer cells. We 
also evaluated the expression of CXCR4 would change the expression of 
CXCL12 by osteoblast cells. 
Statement of purpose 
The purpose of this study was:  
⑴ To establish a 3D in vitro tissue culture model;  
⑵ To evaluate the efficiency of migration of breast cancer cells towards 
osteoblast cells;  
⑶ To test the effects of 1, 25 dihydroxyvitamin D3 in inhibiting osteotropic 
migration; and 
⑷ To apply this model to study one potential mechanism of breast cancer 
bone metastases 
Research questions  
1. Does the matrix provided by the 3D microenvironment aid in forming a more 
efficient in vitro metastatic breast cancer model? 
2. Can 1, 25 dihydroxyvitamin D3 decrease the migration of breast cancer cells 
towards osteoblast cells cultured in collagen scaffolds in a 3D microenvironment? 
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CHAPTER 2  
REVIEW OF LITERATURE 
Introduction of breast cancer 
Breast cancer has a high incidence every year, and is the primary cause of 
cancer death among women worldwide (1). Bone is one of the most preferential 
metastatic target sites for breast cancer. Up to 70% of breast cancer patients will 
develop bone metastasis (2). Bone metastasis can cause severe pain, pathologic 
fractures, life threatening hypercalcemia, spinal cord compression, and other 
nerve compression syndromes (3).  
Bone metastasis of breast cancer is difficult to treat owing to its complexity. 
Current treatments, such as radiation therapy, bisphosphonates, chemotherapy 
and hormone therapy for bone metastatic breast cancer patient only improves the 
quality of life.  If cancer is restricted or localized, radiation therapy is primary 
choice to shrink the tumor and provide pain relief. Systemic therapies such as 
chemotherapy or other drug therapies are usually given to advanced breast 
cancer patients because of the extent of spread of the tumor cells (2). 
In advanced breast cancer,  tumor cells must complete all the steps involved 
in the metastatic cascade: ① proliferation and invasion of cancer cells at primary 
site; ② intravasation, migration in the circulation and extravasation; ③ arrest in 
the bone marrow, egress from central sinus and attachment to bone surfaces; and 
④ colonization of cancer cells and bone destruction(3,4). Bone metastases are 
often in two forms: osteolytic (bone-resorbing) and osteoblastic (bone-forming), 
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and most patients with breast cancer have osteolytic lesions (4).  
Recent research focuses on breast cancer bone metastasis 
The exact mechanism for preferential metastasis is still not well-established. 
Most studies are focused on elucidation of the mechanisms involved in breast 
cancer metastasis to bone. The bone microenvironment is endowed with unique 
biological features that enable circulating cancer cells to metastasize (6). Cancers 
that develop bone metastasis are able to migrate from their primary site, adhere to 
bone and thrive in unique bone environment and ultimately destroy bones. This is 
the basis of the “seed and soil” hypothesis that was put forward by Paget to 
explain the principle of metastasis (3). According to this hypothesis migrated 
cancer cells (seeds) metastasize only to those organs which provide a fertile 
microenvironment (soil) which is congenial for the growth of tumor cells (5). Many 
stem cells such as mesenchymal stem cell and monocytes which are 
hematopoietic, are important players in metastasis (4). The skeletal cells such as 
osteoblasts which have the function of bone formation, and osteoclasts which are 
mainly important for bone resorption, can produce and secrete growth factors, 
including transforming growth factor (TGF)-β, insulin-like growth factors I and II 
(IGF), fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs), 
and bone morphogenetic proteins (BMPs), as well as cytokines such as 
interleukin, macrophage colony-stimulating factor, and tumor necrosis factor-α 
(TNF-α). These growth factors and cytokines are involved in bone resorption via 
the receptor activation of nuclear factor-κB ligand (RANKL) and its two known 
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receptors RANK and OPG (osteoprotegrin) (4-7). While RANK-RANKL axis is 
responsible for the maturation of osteoclasts which in turn facilitate bone 
resorption, OPG, the decoy receptor of RANKL, can effectively decrease 
osteolysis. Metastatic breast cancer cells secrete PTHrP (parathyroid 
hormone-related peptide) in the presence of some bone microenvironment growth 
factors such as TGF- β ， and PTHrP promotes RANKL production and 
RANKL-RANK complex formation thus causing bone resorption. Breast cancer 
cells express a number of genes that may act as homing determinants to facilitate 
their migration to bone. These genes promote invasion and allow extravasation 
from capillaries within bone marrow, genes that confer responsiveness to 
chemotactic cues, and genes that allow adhesion to the bone extracellular matrix 
(2-4). For example, it was demonstrated that CXCR4, a chemokine receptor, is 
highly expressed in breast cancer cells relative to normal breast tissue. Stromal 
cell-derived factor 1 (SDF-1) or CXCL-12, the ligand for CXCR4, which is highly 
expressed in bone, determines the invasion and organ specific metastasis. 
CXCL12 can stimulate cancer cells via CXCR4 signaling, which induces 
chemotaxis and regulate their metastasis to bone (4, 8). Once breast cancer cells 
migrate to bone, they thrive in metabolically active bone environment and 
establish bone metastasis.  
Most research studies on metastatic breast cancer are based on animal in 
vivo models, or two-dimensional (2D) in vitro models. However, these animal 
models are difficult to use for studying molecular mechanisms in the process of 
6 
invasion and migration of tumor cells. Sometimes the host animal tissues are not 
compatible with the implanted human tumors. The tumor response of animal 
models may not be the same as observed in humans (10-13). For 2D models, it is 
convenient to investigate cancer signaling pathways, but the cells grow in a 
different microenvironment from in vivo environments containing ECM 
(extracellular matrix) such as collagen and laminin. They attach to the bottom of 
the culture plates and turn out to be flat while in fact, cells are spherical in vivo, 
and dispersed between interstitial spaces of the ECM. The changes in 
morphology, as well as the differences in cell-cell and cell-matrix interaction from 
the cells in the physiological microenvironment, may decrease the significance of 
the results from 2D models. The development of hypoxia and signaling between 
cells residing within spatially distinct niches, also give rise to the ability of tumor 
aggression, yet these interactions can hardly be reflected in conventional 2D cell 
culture models (9).  
Current three-dimensional (3D) cell culture models 
During the recent years, research on cancer metastasis has gradually turned 
to 3D models because the 3D systems are believed to have greater biological 
relevance than their 2D counterparts. The purpose of this type of tissue culture 
system is to either implant cells in a 3D matrix scaffold; or use more than one type 
of cell or a tissue fragment in combination with another cell type in order to 
recreate the 3D cancer and bone microenvironment (9, 14). Pathi et al utilized 
bone mineral hydroxyapatite to set a 3D model with the neoplastic and bone 
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metastatic growth of breast cancer cells and reported that in the mineralized 
scaffold, breast cancer cells increased adhesion and penetration ability by the 
increased expression of fibronectin (15). Dhurjati et al. developed a 3D 
mineralized multi-cell-layer osteoblast in vitro system in a bioreactor and found 
breast cancer cells’ adhesion, penetration, colony formation were similar to those 
seen in clinical samples. The breast cancer cells could also inhibit osteoblastic 
bone formation by down-regulating synthesis of collagen and osteocalcin. After 
colonization, osteoblast had increased expression of the pro-inflammatory 
cytokine IL-6 (16). Mastro et al. found that this 3D osteoblast system recapitulated 
the process of bone development in vivo including phenotypic change of 
osteoblasts into mature osteocytes, and increased expression of E11, DMP1, and 
sclerostin (17). Krishnan et al then compared such system with traditional 2D 
system and they did not see the tissue penetration or cells files (18). According to 
the above studies, the advantages of 3D models were due to the structure and 
orientation of extracellular matrix in 3D which cannot be present in 2D models. 
They played a critical role in supporting cell functions, transport and overall 
system feasibility.  
Besides the mechanism studies, 3D models are currently used to evaluate 
therapeutic efficacy of anticancer agents in inhibiting tumor growth and metastasis. 
Paduch et al investigated the effects of vitamin D, tamoxifen and β-estradiol on 
breast cancer cell proliferation in 3D tumor spheroid culture system (19). Jin et al 
used a 3D model to investigate adenovirus-mediated antiangiogenesis and 
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oncolysis combination therapy on prostate cancer metastasis (15).  
Currently there are very few studies that compare 3D models vs. 2D or in vivo 
animal models, or apply such models to evaluate the effect of potential anticancer 
agent on bone metastasis 
Vitamin D’s role in breast cancer bone metastasis 
Vitamin D is well-known for its ability in inhibiting proliferation and promoting 
differentiation of cancer cells, yet there are few studies that report the effect of 
vitamin D on cancer metastasis. Some studies have demonstrated the potential of 
vitamin D in reducing prostate cancer metastasis by blocking gene Stat 3, which 
encodes interleukin-12, an osteoclastic metastasis induced factor (20, 21). 
Mork-Hansen et al demonstrated that 1, 25 dihydroxyvitamin D3 inhibits invasion 
of breast cancer cells in 2D in vitro models, although the mechanism is not clear 
(22). Wang et al showed the potential of vitamin D in preventing cancer metastasis: 
low serum vitamin D level (< 20ng/ml) is prevalent in patients with breast cancer 
bone metastasis and is in conjunction with increased toxicity from bisphosphonate 
therapy (23). Vitamin D deficiency is associated with promoted growth of human 
breast cancer cells in the bones, with the secondary changes in the bone 
microenvironment and direct effects of it on tumor growth (10). Vitamin D analog 
EB 1089 decreased the total number of bone metastases, the mean surface area 
of osteolytic lesions, and tumor burden, and prolonged survival time (11).  
Currently it is not clear whether vitamin D supplementation has a direct effect 
on metastasis since no significant changes in the bone resorption markers have 
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been observed although there was a significant reduction in the number of sites of 
pain (24).  
There remain large gaps in our understanding regarding the biological targets 
or down stream signaling pathways modulated by vitamin D even in the models 
which proved vitamin D has positive effect in affecting metastasis. The 
inconsistent results, along with the elucidation of underlying mechanisms in the 
positive studies, make it necessary to clarify the role of vitamin D in breast cancer 
metastasis. 
Future implications 
In conclusion, an appropriate 3D model is a useful experimental tool. The 
advantages of it include: 1) cell morphology and signaling are more similar to 
those in physiological conditions than 2D cell culture models; 2) more applicable 
to implement rapid experimental manipulations than animal models. However, 
there are not many well-established 3D models, especially in breast cancer 
research. The existing ones vary in their ability to mimic in vivo tissue conditions 
according to their designs and the materials they use, and lack vasculature and 
normal transport of small molecules, host immune responses, and other cell-cell 
interactions. Therefore, the aim of the future study is to establish a new 
sustainable 3D tissue system to simulate the bone metastasis of breast cancer in 
vitro and then to utilize this system to screen different dietary agents for their 
anti-metastatic role. 
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CHAPTER 3 
METHODS 
The purpose of this study is to establish a new sustainable in vitro 3D tissue 
culture system to mimic the bone metastasis of breast cancer and use the system 
to test the effect of vitamin D on breast cancer bone metastasis.  
Cell lines 
Murine pre-osteoblast cell line, MC3T3-E1 was purchased from American 
Type Culture Collection (Manassas, VA), and human breast cancer cell line, 
MDA-MB-231, was generously provided by Roy Jensen (The University of Kansas 
Cancer Center, KU Medical Center, Kansas City)  
Establishment of 2D and 3D in vitro models  
Before cell culture, the collagen composite scaffolds (BD Biosciences, MA) 
were sterilized by immersing in 70% ethanol for 20 minutes followed by three 
washes with sterile HBSS (Hank's Buffered Salt Solution) (Fisher Scientific, IL) 
and primed by pre-incubating in complete medium (Dulbecco’s Modified Eagle’s 
Medium, with 10% fetal bovine serum) (Fisher Scientific, IL) overnight. 
Twenty-four-well tissue culture plates were used to grow the cells while 
seeding density in each well was 5×105 MC3T3-E1 cells for 2D system, and the 
same amount per scaffold for 3D system. Each well contained one scaffold with 
cells. Cells were grown in complete medium, and were maintained in a 5% CO2 
incubator held at 37⁰C. The osteoblast cells were cultured for 15 days in complete 
medium supplemented with differentiation agents (10-7M dexamethasone 
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(Sigma-Aldrich Co., MO), 50µM ascorbic acid (Sigma-Aldrich Co., MO), 10 nM 
1,25 dihydroxyvitamin D3 (Enzo Life Sciences, Inc.,PA), 10nM β-glycerol 
phosphate (Sigma-Aldrich Co., MO). 
Osteoblasts conditioned media (OBCM) collection 
On day 15, the osteoblasts growing with (3D) or without scaffolds (2D) were 
cultured in serum free complete medium. The OBCM from both 2D and 3D 
cultures were collected on day 16.  
Breast cancer conditioned media (BCCM) collection 
Sub-confluent (90%) MDA-MB-231 cells were pre-treated with 100nM 1, 25 
dihydroxyvitamin D3 for 48 hours. After 48 hours, serum free complete medium 
were used to culture the cells for another 24 hours. This serum free medium was 
collected as pre-treated BCCM. As control, serum free complete medium were 
used to culture the untreated sub-confluent breast cancer cells for 24 hours and 
were collect. 
Pre-treated and untreated breast cancer cell collection 
After collection of the conditioned media from pre-treated and untreated 
MDA-MB-231 cells, the cells were harvested and were used for cell migration 
assay. 
Cell migration assay 
Cell migration assay is based on the principle of Boyden chamber. The 24 
well plates were used for migration assay. The wells with cells were designated as 
lower chambers, and PCF (polycarbonate) inserts with 8µm pore size (Millipore, 
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MA) as upper chambers. We seeded pre-treated and untreated MDA-MB-231 
cells at a density of 1×105 cells per insert, respectively. The experimental 
combinations were as follows: untreated MDA-MB-231 in 2D system, untreated 
MDA-MB-231 in 3D system, treated MDA-MB-231 in 2D system, and treated 
MDA-MB-231 in 3D system. After 24 hours, the inserts were removed and stained 
with crystal violet.   
Determination of cell migration 
The cells on the inner surface of the membranes of each insert were 
swabbed. The membranes were immersed in 0.05% crystal violet solution for 30 
minutes. The membranes were washed with distilled water three times and dried 
at ambient temperature. Pictures of migrated cells were taken with a digital 
microscope (Nikon, NY), and the number of migrated cells were counted and 
recorded.   
Treatment of vitamin D pretreated breast cancer cells with OBCM  
Pre-treated and untreated MDA-MB-231 cells were seeded in each well of 6 
well plates at the density of 1×105. The cells were cultured in 2D and 3D CM for 
48 hours, respectively. The conditioned media consisted of one half volume 
OBCM and one half volume complete medium.  
Detection of CXCR4 expression on the surface of breast cancer cells by 
Flow Cytometry  
After culturing in OBCM for 48 hours, 1, 25 dihydroxyvitamin D3 pre-treated 
and untreated MDA-MB231 cells were stained with PE-conjugated anti-CXCR4 
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mAb (FAB170P, Clone 12G5) (R&D Systems, Minneapolis, MN). PE-conjugated 
mouse IgG2a isotype-matched mAb (IC003P, R&D Systems) was used as the 
negative control. Flow cytometry was used to detect cell surface expression of 
CXCR4 and FlowJo (Tree Star, Inc., OR) was used to analyze the data. 
Treatment of osteoblasts (2D vs. 3D) with BCCM  
MC3T3-E1 cells were seeded at the density of 1×105 cells per well in 6 well 
plates and cultured in complete medium with differentiation agents for 1 day. To 
create the 3D system, each well had 2 scaffolds while the 2D system had 
MC3T3-E1 cells only. Complete media were replaced by pre-treated and 
untreated conditioned media to culture 2D and 3D osteoblasts for 24 hours, 
respectively. Conditioned media consisted of one half volume BCCM and one half 
volume complete medium.  
Detection of CXCL12 expression on the surface of osteoblasts by 
quantitative real-time polymerase chain reaction (qRT-PCR) 
    Quantitative real-time PCR (qRT-PCR) was used to detect the expression of 
CXCL 12 by MC3T3-E1 in 2D and 3D system. RNA was obtained by the RNeasy 
minikit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Prior 
to isolating total RNA from cells embedded in 3D scaffolds, the scaffolds were 
chopped by microscissors and centrifuged at the speed of 10,000 x g for 5 
minutes. The precipitation was used for RNA isolation. Quantitative real-time PCR 
was performed according to the protocol. The cycling condition was: 50.0 ºC for 
20 min, 95.0 ºC for 12.5 min, 40 cycles of 94.0 ºC for 15 sec, 57.0 ºC for 20 sec, 
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72.0 ºC for 1 min, 75 cycles of 55.0 ºC for 10 sec, and 25.0 ºC for hold. The 
transcript levels were normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) mRNA. 
Statistics 
All data are presented as the mean ± SD. Data were analyzed by two-sided 
Student's t test. Each experiment replicated three times and a minimum of three 
samples per experiment. A p value < 0.01 was considered statistically significant. 
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CHAPTER 4   
RESULTS 
Three-dimensional microenvironment increased the mobility of breast 
cancer cells, and 1, 25 dihydroxyvitamin D3 decreased the mobility of breast 
cancer cells 
To examine the effects of dihydroxyvitamin D3 and 3D microenvironment on 
breast cancer metastatic ability, MDA-MB-231 were exposed to complete medium 
with or without 100nM vitamin D for 48 hours cultured in 2D system or 3D system. 
Breast cancer cell migration through a microporous membrane was assessed. We 
observed the exposure of both pre-treated and untreated breast cancer cells had 
significantly (p ≤ 0.0001) increased migration ability in 3D system compared 
with those in 2D system. Approximately 100% more MDA-MB-231 cells per field 
of view were chemoattracted by the 3D tissue culture system. Vitamin D 
decreased breast cancer cell migration significantly in both 2D and 3D systems in 
vitro by about 50% (Figure 1, Figure 2).  
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a. 2D-1,25D3   b. 2D+1,25D3   c. 3D-1,25D3   d. 3D+1,25D3 
Figure 1.  Images of vitamin D pre-treated and untreated breast cancer 
migration in 2D and 3D microenvironment. 1, 25 dihydroxyvitamin D3 
pre-treated and untreated breast cancer MDA-MB-231 cells growing in inserts 
(upper chamber) were exposed to 2D or 3D systems (lower chambers) for 24 
hours, and then migrated cells were stained with crystal violet. Black arrows 
indicate stained migrated MDA-MB-231 cells. Red arrows refer to the pores of the 
insert membranes. (a: untreated MDA-MB-231 cells in 2D osteoblast system; b: 
pre-treated MDA-MB-231 cells in 2D osteoblast system; c: untreated 
MDA-MB-231 cells in 3D osteoblast system; d: pre-treated MDA-MB-231 cells in 
3D osteoblast system) 
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Figure 2.  Migration Rate of vitamin D pre-treated and untreated breast 
cancer cells through a microporous membrane in the 2D and 3D system.  
* *p ≤ 0.0001 
2D: MDA-MB-231 cells in 2D osteoblast system; 3D: MDA-MB-231 cells in 3D 
osteoblast system; +1,25D3: 1, 25 dihydroxyvitamin D pre-treated breast cancer 
cells; -1,25D3: untreated breast cancer cells. 
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1, 25 dihydroxyvitamin D pre-treated breast cancer cells express less 
CXCR4 than untreated breast cancer cells 
To identify a potential mechanism for the decreased metastatic ability of 1, 25 
dihydroxyvitamin D pretreated breast cancer cells (2-4), the expression of CXCR4 
was investigated since it is known to have a role in the migration and homing of 
several cancer cells including breast cancer (ref). The pre-treated and untreated 
MDA-MB-231 cells were cultured in 2D and 3D CM and then assess the cell 
surface expression of CXCR4 by flow cytometry. In both 2D and 3D CM, the 
expression of CXCR4 by vitamin D pre-treated breast cancer cells decreased 
significantly when compared with untreated breast cancer cells. The data are 
shown in Figure 3. 
 
 
-1,25D3,2D  +1,25D3,2D  -1.25D3, 3D +1,25D3, 
A
. 
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Figure 3.  Comparison of vitamin D treated and untreated breast cancer cell 
surface expression of CXCR4. Human breast cancer cell line MDA-MB-231 
were cultured complete medium with 100nM 1, 25 dihydroxyvitamin D3, or 
complete medium for 48 hours. The pre-treated and untreated cells were exposed 
to 2D or 3D OBCM, respectively.  Cell surface expression of CXCR4 was 
analyzed by FlowJo software (A). Data are expressed as the mean ± SD of the 
percent of cells express CXCR4. *p ≤ 0.05 (B). 2D: MDA-MB-231 cells in 
conditioned medium from 2D osteoblast system; 3D: MDA-MB-231 cells in 
conditioned medium from 3D osteoblast system; +1,25D3: 1, 25 dihydroxyvitamin 
D pre-treated MDA-MB-231 cells; -1,25D3: untreated MDA-MB-231 cells. 
 
 
 
 
 
 
 
B 
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Breast cancer cells do not express more CXCR4 when growing in 3D CM 
The expression levels of CXCR4 in breast cancer cells growing in 2D and 3D 
CM were also compared. No significant differences in CXCR4 expression by 
either vitamin D pre-treated or untreated breast cancer cells were found. The data 
are shown in Figure 4. 
A
 
-1,25D3, 2D  +1,25D3, 2D  -1.25D3, 3D    +1,25D3, 3D 
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B 
 
Figure 4.  Comparison of breast cancer cell surface expression of CXCR4 
in 2D and 3D conditioned medium. Human breast cancer cell line MDA-MB-231 
were cultured complete medium with 100nM 1, 25 dihydroxyvitamin D3, or 
complete medium for 48 hours. The pre-treated and untreated cells were exposed 
to 2D or 3D OBCM, respectively.  Cell surface expression of CXCR4 was 
analyzed by FlowJo software (A). Data are expressed as the mean ± SD of the 
percent of cells express CXCR4. *p ≤ 0.05 (B) 
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Treated BCCM (Breast cancer CM prepared from vitamin D treated cells) 
does not decrease the expression of CXCL12 by osteoblast cells 
In order to ascertain whether CXCL12, the ligand of CXCR4 is increasingly 
expressed by osteoblast cells in response to the rising level of CXCR4, both 2D 
and 3D osteoblast cells were cultured in pre-treated and untreated BCCA CM for 
2days, and qRT-PCR was used to detect changes in the expression of CXCL12 
mRNA. We did not find any significant differences in CXCL12 expression by 
osteoblast cells in the presence of either pre-treated CM or untreated CM. The 
data are shown in Figure 5. 
 
Figure 5.  Gene expression in osteoblasts cultured in vitamin D pre-treated 
and untreated BCCM. 1, 25 dihydroxyvitamin D pretreated and untreated BCCM 
were used to cultured 2D osteoblast cells and 3D osteoblast cells, respectively. 
Transcript levels of CXCL12 in osteoblast cells were quantified by qRT-PCR and 
normalized to GAPDH. *p ≤ 0.05 
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Osteoblasts growing in collagen scaffolds do not express more CXCL12 
The expression of CXCL12 by 2D and 3D osteoblasts were also compared in 
this study. By quantitative real time PCR, we did not see any significant difference 
between 2D and 3D osteoblasts, either in pre-treated or untreated BCCM. The 
data are shown in Figure 6.  
 
 
Figure 6.  Gene expression in the MDA-MB-231 culturing in 2D and 3D 
microenvironment. 1, 25 dihydroxyvitamin D3 pretreated and untreated BCCM 
were used to cultured 2D osteoblast cells and 3D osteoblast cells, respectively. 
Transcript levels of CXCL12 in osteoblast cells were quantified by qRT-PCR and 
normalized to GAPDH. *p ≤ 0.05 
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CHAPTER 5   
DISCUSSION 
To evaluate the breast cancer metastasis, we created 3D system by culturing 
the osteoblasts in collagen scaffolds, which provided a spatial culture 
microenvironment to mimic the in vivo situation, and compare the cancer 
migration in this system and in 2D cell-monolayer system. We found breast 
cancer cells migrated about twice in this 3D system than in the 2D 
microenvironment. It suggested that the 3D system is more sensitive for breast 
cancer migration and might be better for studying metastatic breast cancer.  
There are existing studies revealing correlation between vitamin D and breast 
cancer metastasis (16, 19-22). In our study, we found in the 2D system, the rate of 
migrated 1, 25 dihydroxyvitamin D3 pre-treated breast cancer cells was only 50% 
of the untreated cells. Similar results were also found in the 3D system as there 
was a 40% decrease rate. We conclude that 1, 25 dihydroxyvitamin D3 could 
prevent breast cancer migration. We also compared the data from pre-treated 
breast cancer cells growing in 2D and 3D system. In the 3D microenvironment, 
vitamin D’s anti-migration activity was weaker than that in 2D, for there were more 
migrated cells as well as the less decreasing migration rate. It seems likely that 
the collagen matrix in the microenvironment is also an important factor to 
influence the anti-tumor activity of 1, 25 dihydroxyvitamin D3. It supports our 
hypothesis that the 3D system of osteoblasts growing in the supportive scaffolds 
may provide more protective and chemoattractive agents. These data 
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demonstrate that the vitamin D pre-treatment worked, and the 3D model worked 
better. 
CXCR4 is important in breast cancer migration (25). In order to investigate 
whether the increased sensitivity of 3D system was caused by the increased 
expression of CXCR4 in breast cancer cells, and the inhibition of migration by 1, 
25 dihydroxyvitamin D3 was the result of suppressing expression of CXCR4, 
changes in the expression of CXCR4 of MDA-MB 231 cells cultured in the 2D and 
3D osteoblast conditioned media were monitored. In our study, vitamin D 
pretreated breast cancer cells expressed less CXCR4 than untreated cells while 
having less migration rate. It indicates that vitamin D may suppress the migration 
of breast cancer by downregulating the cell surface expression of CXCR4 so it 
could be the direct target of vitamin D. No differences between the breast cancer 
cells growing in the 2D and 3D OBCM were seen. This might point out that 
CXCR4 is not a factor which is affected by the supporting matrix in bone 
microenvironment or there may be other cells or factors in the BME (which were 
not available in the current model) whose presence might be necessary to 
modulate the expression of CXCR4 in breast cancer cells.  
As we hypothesized the increased migration rate was caused by the 
CXCR4-CXCL12 axis, we also detected the osteobalst expression of CXCL12 
since it is the ligand of CXCR4 and theoretically the mount of it should be 
consistent with the expression of CXCR4. We observed that there were no 
significant differences in CXCL12 level between 2D and 3D osteoblasts culturing 
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in BCCM. It could possibly be the reason that the collagen supporting matrix could 
not increase the expression of CXCL12. Along with the non-significant difference 
between the breast cancer cells’ expression of CXCR4 in the two systems, we 
can say the better sensitivity of 3D system is not the result of CXCR4-CXCL12 
axis.   
The breast cancer and osteoblast interact with each other not only by the 
CXCR4-CXCL12 axis, but some other factors as well. For example, the breast 
cancer cells can overproduce PTHrP, which can increase the osteolytic 
metastasis. Meanwhile, TGF-β, secreted from the bone matrix, stimulate the 
cancer cells to produce more PTHrP, thus establishing a positive feedback loop 
(26). PTHrP works in both RANKL dependent and independent mechanisms 
(27-30). In addition, IL-8 also belongs to the CXC chemokine family, is over 
expressed in MDA-MB-231 cell line (30). It can stimulate early metastasis by 
initiating bone resorption process (28). The higher sensitivity of the 3D system 
could possibly be due to these factors. Osteoblasts can produce some growth 
factors such as IGF, TGF-β, FGF, and BMPs, which may incorporated into bone 
matrix (2, 3). They are released into bone microenvironment and make it attractive 
to the cancer cells (31). As the scaffolds provide the collagen, one of the main 
component of bone extracellular matrix to the osteoblasts, there might be an 
accumulation of such factors in the matrix and when we co-culture the breast 
cancer cells with osteoblasts, osteolysis begins thus these factors are released 
and attract the cancer cells. It could be another potential explanation for the 
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sensitivity of 3D models.  
Limitation 
To our knowledge, this is the first model to create the 3D bone 
microenvironment for metastatic breast cancer with collagen matrix scaffolds. 
One limitation in the design could be that in this study, the 3D model only includes 
osteoblasts and extracellular matrix. However, bone microenvironment is complex 
and harbors other types of cells such as osteoclasts, marrow stromal cells, 
vascular endothelial cells, and immune cells. These cells interact with each other 
and mediate the signaling pathways that are critical for adhesion, migration, and 
homing of breast cancer cells in the bone microenvironment. The current 3D 
model does not completely justify the complexity of the in vivo bone 
microenvironment. 
Another limitation of our study was the difficulty of quantifying the cells in the 
3D system. Although the initial seeding densities in both models were the same, it 
is possible that with the support of collagen matrix, the osteoblasts grew better 
and proliferate faster in 3D tissue culture system. Along with the fact that it is 
difficult to measure the number of osteoblasts in each scaffold, we cannot exclude 
the fact that the difference in the migration rate was caused by the difference of 
osteoblast numbers in the lower chamber due to better proliferation rates in 3D vs. 
2D system. For future studies, a proliferation assay such as MTS assay or Ki 67 
immunohistochemical staining should be included to quantify proliferating 
osteoblasts in 2D vs. 3D systems. If there were much more osteoblasts in the 
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lower chamber in 3D system than the 2D one, the chemoattractive factors’ 
concentration could be higher, which would increase the migration rate.  
In addition, the method of collecting osteoblast conditioned media could be 
another limitation. We denied our hypothesis that the increased migration in the 
3D model was the consequence of CXCR4-CXCL12 axis because we did not find 
the increased CXCR4 production in breast cancer cells culturing in 3D OBCM. 
However, our hypothesis could still be reasonable because according to a study 
performed by Junga et al, MC3T3-E1 secreted high levels of CXCL12 into media 
early in culture, and the levels decreased as matrix deposition and mineralization 
proceeded over time (32). Because the OBCM we used were collected at day 15, 
and at this time the osteoblasts were already highly differentiated and mineralized, 
the OBCM might not have enough CXCL12 so the breast cancer cells would not 
produce more CXCR4 in response to CXCL12.  
Implications 
In our current study, we established a novel 3D in vitro model of bone 
metastatic breast cancer, and found that it was much more sensitive than the 
traditional 2D tissue culture system. Although we did not find the potential 
mechanism which caused the higher sensitivity, the results suggest a practical 
strategy of using such model to support further studies of breast cancer bone 
metastasis. We also investigated vitamin D’s ability to inhibit breast cancer 
migration by downreguating the production of CXCR4. It suggests that this model 
can also provides a relatively ideal approach to test new drugs during the process 
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of drug development and therapies related to this disease, as well as uncover the 
mechanisms. It also indicates that vitamin D is likely a preventative agent for 
breast cancer migration.  
Future studies 
In this study, we only find a phenomenon that the 3D model was more 
sensitive in causing breast cancer migration. Looking for an appropriate method 
to adjust the difference in osteoblast number between 2D and 3D models will be 
needed in future studies to exclude the confounding factors and strengthen our 
findings. The mechanisms behind the findings should also be included in the 
future studies to make it more convincing. As the OBCM could be a possible 
limitation, we can try to assess the effects of co-culture with breast cancer cells 
and osteoblast 2D vs. 3D instead of BCCM on CXCL12 expression. 
As we have found that 100nM 1, 25 dihydroxyvitamin D3 could decrease the 
migration of breast cancer cells probably by downregulating the expression of 
CXCR4. However, we did not demonstrate that this downregulation was not the 
effects of the decreased cell viability caused by the vitamin D treatment. In the 
future study, assays testing breast cancer viability should be applied.  
Conclusion 
The lack of ideal in vitro tissue culture systems of breast cancer metastasis to 
bone is a significant problem in current breast cancer research. We compared a 
3D tissue culture system with traditional 2D system for breast cancer metastasis, 
and proved that this 3D system was more sensitive. With this tissue culture 
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system, the impact of vitamin D on the migration of breast cancer cells was 
demonstrated, and the down regulation of CXCR4 expression was identified as a 
potential mechanism of inhibition by 1, 25 dihydroxyvitaminD3.  
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APPENDIX A 
CRYSTAL VIOLET STAINING 
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Crystal Violet Staining 
1. Prepare for staining by flattening the tips of 10-20 swabs by pressing the head 
of swab firmly against a clean surface. These will be used to remove the cells. 
2. Using a clean disposable pipette tip for each well, remove medium from the 
chamber. 
3. Transfer the chambers to a clean, empty well of the plate. Add 6 drops of 
solution to each well, incubate for 20 min. 
4. Using the forceps, grasp and remove the chambers. Wash excess stain from 
the chamber by gently dipping several times into distilled water. Flick off 
excess water and allow to air dry. 
5. Observe under the electronic microscope.   
 
